NCI Center for Cancer Research shared a post on LinkedIn:
“CD22 CAR T-cell immunotherapy is an effective treatment for several types of cancer, with a recent clinical trial showing a 70% response rate.
Researchers wanted to know more about why 30% of patients’ cancers didn’t respond: the answer may lie in the baseline condition of their immune cells. Read more about this CCR study, led by Nirali Shah, from our Pediatric Oncology Branch.
Learn more about research in our Pediatric Oncology Branch.
Image: Microscopy image of B-cell acute lymphoblastic leukemia.
Credit: iStock.”
